February 1999
Chemical Market Reporter;02/15/99, Vol. 255 Issue 7, p14
Trade Publication
Reports on news briefs concerning several pharmaceutical and fine chemicals. Recommendation given by the European Committee for Proprietary Medicinal Products to Ivax Corp.'s Paxene (paclitaxel) for the treatment of AIDS-related Kaposi's sarcoma; Information on the collaboration deal signed by RTP Pharma Inc. with Phasex Corp.


Related Articles

  • IVAX GETS APPROVAL TO MARKET PAXENE IN CANADA.  // Worldwide Biotech;Jun2000, Vol. 12 Issue 6, p5 

    Reports that IVAX Corp. has received approval to market its propriety anti-cancer drug, Paxene (paclitaxel), in Canada for the treatment of AIDS-related Kaposi's sarcoma in patients who have failed prior liposomal anthracycline therapy.

  • Ivax Corp. Receives Patent for Oral Paclitaxel. Krause, Carey // Chemical Market Reporter;6/18/2002, Vol. 259 Issue 25, p12 

    Reports on the patent for an oral formulation of paclitaxel received by Ivax Corp. from the U.S. Patent and Trademark Office. Advantages offered by the oral form of paclitaxel; Predicted sales of the drug; Benefits of the oral form of paclitaxel in improving the market potential for Ivax.

  • Generics Win Two.  // Pharmaceutical Executive;Feb2002, Vol. 22 Issue 2, p28 

    Reports on a court ruling in favor of generics for American BioScience's Taxol. Plan of Ivax to pursue claims against American BioScience and BristolMyers Squibb.

  • Ivax Gains Favorable Ruling in Taxol Dispute.  // Chemical Market Reporter;09/11/2000, Vol. 258 Issue 11, p17 

    Reports on the decision of the United States Food & Drug Administration to de-list the anti-cancer drug paclitaxel of Ivax Corp. Details on the court decision; Validity of the anti-cancer drug patent; Information on the drug patent requirement set by the federal agency.

  • Ivax Shores Up Two Additional Paclitaxel Makers.  // Chemical Market Reporter;6/4/2001, Vol. 260 Issue 23, p3 

    Reports on the decision of the United States Food and Drug Administration (FDA) to approve two additional drug makers to manufacture the Onxol or paclitaxel drug of Ivax Corp. Failure of Ivax to meet the increased demand for Onxol; Significance of the FDA decision to Ivax; Pharmaceutical...

  • Ivax gains recommendation in Europe for injectable paclitaxel anticancer drug.  // PharmaWatch: Cancer;March 2004, Vol. 3 Issue 3, p18 

    Reports on the European Medicines Evaluation Agency's recommendation of the extension of the marketing authorization for Ivax Corp.'s proprietary injectable Paclitaxel to include the treatment of metastatic breast cancer and metastatic ovarian cancer. Identification of Paclitaxel as the active...

  • Ivax, BMS Suit Up In Taxol Legal Battle.  // Chemical Market Reporter;08/21/2000, Vol. 258 Issue 8, p20 

    Reports on the legal battle between Ivax Corporation and Bristol-Myers Squibb (BMS) over a generic version of Bristol-Myers' anti-cancer drug paclitaxel. Lawsuit filed by American BioScience Inc. against BMS; Details on American BioScience's motion for a preliminary injunction; Requirements...

  • Ivax Wins Round in Paclitaxel Patent Battle, Is Likely to Remain. Krause, Carey // Chemical Market Reporter;1/21/2002, Vol. 261 Issue 3, p12 

    Reports that Ivax Corp. has won a patent lawsuit battle with American BioSciences Inc. (ABI) at a federal district court in California over its paclitaxel, an anticancer generic drug. ABI plans on the court ruling; Competition in the United States paclitaxel market; Projected sales growth of...

  • Ivax receives expanded approval for cancer drug.  // PharmaWatch: Cancer;April 2004, Vol. 3 Issue 4, p18 

    Focuses on the European Commission's expanded approval of Paxene, Ivax Corp.'s injectable form of the cancer drug paclitaxel, to cover the treatment of metastatic breast cancer and metastic ovarian cancer. Ivax's deal with Mayne Group Ltd. concerning marketing and distribution of Paxene in Europe.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics